5-[5-(2-chlorophenyl)-1H-imidazol-2-yl]-3-phenyl-1H-pyrazol-4-ol | 1197337-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[5-(2-chlorophenyl)-1H-imidazol-2-yl]-3-phenyl-1H-pyrazol-4-ol
• CAS: 1197337-75-9
• 化学式: C₁₈H₁₃ClN₄O
• 分子量: 336.78
• InChiKey: JAZPYGHOCUICLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.6
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Clasby Martin C.

  公开号：US20110065682A1

  公开（公告）日：2011-03-17

  The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

  本发明涉及公式I-III的新型杂环化合物，如本文所述或其药学上可接受的盐、溶剂化物、酯、前药或立体异构体。还揭示了包含该化合物的制药组合物，以及使用该化合物治疗或预防血栓栓塞性疾病的方法。
• Heterocyclic compounds as factor IXA inhibitors.
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2805939A1

  公开（公告）日：2014-11-26

  The present invention relates to novel heterocyclic compounds of Formulae I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

  本发明涉及式 I 的新型杂环化合物： 或其药学上可接受的盐、溶液剂、酯、原药或立体异构体。还公开了包含所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓栓塞性疾病的方法。
• US8148363B2
  申请人：——

  公开号：US8148363B2

  公开（公告）日：2012-04-03
• [EN] HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DU FACTEUR IXA
  申请人：SCHERING CORP

  公开号：WO2009143039A2

  公开（公告）日：2009-11-26

  The present invention relates to novel heterocyclic compounds of Formulae I-III: Formula I; [Chemical Formulas should be inserted here as they appears on abstract in.pdf form.] Formula II; Formula III as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.